Fresenius (ETR:FRE) stock price target increased to 74.00EUR, issued a report today by Bankhaus Lampe KG
- Updated: October 10, 2016
In a report released on 10/10/2016 Bankhaus Lampe KG increased the stock price target of Fresenius (ETR:FRE) to 74.00EUR indicating a possible upside of 0.04%.
Previously on 9/26/2016, Joh. Berenberg Gossler & Co. KG reported on Fresenius (ETR:FRE) increased the target price from 0.00EUR to 77.25EUR. At the time, this indicated a possible upside of 0.06%.
Yesterday Fresenius (ETR:FRE) traded 0.00% even at 71.32EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 0
See Chart Below
Fresenius has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR Fresenius’s market capitalization is currently 0 EUR.
About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.